{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:13:34Z","timestamp":1790856814512,"version":"4.1.0"},"reference-count":142,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.ekir.2025.09.010","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T15:54:29Z","timestamp":1757606069000},"page":"3757-3772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antiphospholipid Syndrome and the Kidney"],"prefix":"10.1016","volume":"10","author":[{"given":"Maxime","family":"Taghavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Roccatello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savino","family":"Sciascia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2025.09.010_bib1","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1136\/ard-2023-224609","article-title":"2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"82","author":"Barbhaiya","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2025.09.010_bib2","doi-asserted-by":"crossref","first-page":"SI24","DOI":"10.1093\/rheumatology\/kead571","article-title":"Epidemiology of antiphospholipid syndrome: macro- and microvascular manifestations","volume":"63","author":"Gaspar","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ekir.2025.09.010_bib3","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11926-021-01038-2","article-title":"Epidemiology of antiphospholipid syndrome in the general population","volume":"23","author":"Dabit","year":"2022","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.ekir.2025.09.010_bib4","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nrrheum.2017.124","article-title":"Diagnosing antiphospholipid syndrome: \u201cextra-criteria\u201d manifestations and technical advances","volume":"13","author":"Sciascia","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ekir.2025.09.010_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/antib13010021","article-title":"Diagnosis and management of catastrophic antiphospholipid syndrome and the potential impact of the 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"13","author":"Jacobs","year":"2024","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.ekir.2025.09.010_bib6","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jtha.2024.10.022","article-title":"An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"23","author":"D\u00e9verse","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ekir.2025.09.010_bib7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jtha.2024.09.021","volume":"23","author":"Meroni","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ekir.2025.09.010_bib8","article-title":"Non-criteria antiphospholipid antibodies in antiphospholipid syndrome: diagnostic value added","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2025.09.010_bib9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrneph.2014.38","article-title":"Renal involvement in antiphospholipid syndrome","volume":"10","author":"Sciascia","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2025.09.010_bib10","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3899\/jrheum.2022-1200","article-title":"Efforts to better characterize \u201cantiphospholipid antibody nephropathy\u201d for the 2023 ACR\/EULAR antiphospholipid syndrome classification criteria: renal pathology subcommittee report","volume":"51","author":"Barbhaiya","year":"2024","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ekir.2025.09.010_bib11","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1093\/rheumatology\/keae583","article-title":"ANA-positive versus ANA-negative antiphospholipid antibody-positive Patients: results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (\u201cRegistry\u201d)","volume":"64","author":"Cecchi","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ekir.2025.09.010_bib12","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/art.10187","article-title":"Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients","volume":"46","author":"Cervera","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ekir.2025.09.010_bib13","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2215\/CJN.00460110","article-title":"Renal involvement in primary antiphospholipid syndrome: retrospective analysis of 160 patients","volume":"5","author":"Sinico","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.09.010_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103158","article-title":"Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: a systematic review and meta-analysis","volume":"21","author":"Domingues","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ekir.2025.09.010_bib15","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.20433","article-title":"Antiphospholipid syndrome nephropathy in patients with systemic lupus erythematosus and antiphospholipid antibodies: prevalence, clinical associations, and long-term outcome","volume":"50","author":"Tektonidou","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ekir.2025.09.010_bib16","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1681\/ASN.V15777","article-title":"Anti-cardiolipin antibody and renal disease: a report three cases","volume":"1","author":"D\u2019Agati","year":"1990","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.09.010_bib17","first-page":"254","article-title":"Systemic and renal fibrinolytic activity in a patient with anticardiolipin syndrome and renal thrombotic microangiopathy","volume":"10","author":"Becquemont","year":"1990","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.ekir.2025.09.010_bib18","first-page":"1181","article-title":"Renal involvement in primary antiphospholipid syndrome","volume":"19","author":"Amigo","year":"1992","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ekir.2025.09.010_bib19","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1681\/ASN.V103507","article-title":"The intrarenal vascular lesions associated with primary antiphospholipid syndrome","volume":"10","author":"Nochy","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.09.010_bib20","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ekir.2025.09.010_bib21","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0272-6386(03)00352-4","article-title":"The expanding spectrum of renal diseases associated with antiphospholipid syndrome","volume":"41","author":"Fakhouri","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.09.010_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae017","article-title":"Membranous nephropathy in primary antiphospholipid syndrome","volume":"17","author":"Stammler","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.09.010_bib23","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12882-020-01856-z","article-title":"Primary antiphospholipid syndrome associated with anti-phospholipase A2 receptor antibody-positive membranous nephropathy","volume":"21","author":"Teisseyre","year":"2020","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2025.09.010_bib24","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/acr.22200","article-title":"Association of thrombotic microangiopathy and intimal hyperplasia with bleeding post-renal biopsy in antiphospholipid antibody-positive patients","volume":"66","author":"Jordan","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ekir.2025.09.010_bib25","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1093\/ndt\/gfz085","article-title":"Safety and effectiveness of transjugular renal biopsy for systemic lupus erythematosus and antiphospholipid antibody syndrome patients taking antithrombotics","volume":"35","author":"Nielly","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.09.010_bib26","first-page":"96","article-title":"Positivity of antiphosphatidylserine\/prothrombin antibodies identifies a subgroup of more severe antiphospholipid syndrome patients","volume":"43","author":"Delarue","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ekir.2025.09.010_bib27","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1053\/j.ajkd.2022.10.014","article-title":"Renal thrombotic microangiopathy: a review","volume":"81","author":"Genest","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.09.010_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae302","article-title":"Anti-phospholipid antibodies nephropathy is associated with an increased risk of kidney failure: a systematic literature review and meta-analysis","volume":"17","author":"Hoxha","year":"2024","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.09.010_bib29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/09612033231217351","article-title":"The estimated prevalence of antiphospholipid antibodies and criteria-antiphospholipid syndrome in subjects with renal thrombotic microangiopathy","volume":"33","author":"Aluf","year":"2024","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2025.09.010_bib30","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00296-018-4040-2","article-title":"Renal involvement in antiphospholipid syndrome","volume":"38","author":"de Azevedo","year":"2018","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ekir.2025.09.010_bib31","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1177\/0961203320940776","article-title":"Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry","volume":"29","author":"Zuily","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2025.09.010_bib32","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.ekir.2023.01.018","article-title":"Clinical-pathological characteristics of renal injuries identify different clusters in patients with antiphospholipid antibodies","volume":"8","author":"Sciascia","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2025.09.010_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109735","article-title":"Antiphospholipid syndrome nephropathy: current knowledge and unanswered questions","volume":"255","author":"Xourgia","year":"2023","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ekir.2025.09.010_bib34","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1053\/j.ajkd.2019.08.032","article-title":"mTORC pathway activation and effect of sirolimus on native kidney antiphospholipid syndrome nephropathy: A case report","volume":"76","author":"Dufour","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.09.010_bib35","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1056\/NEJMoa1312890","article-title":"Inhibition of the mTORC pathway in the antiphospholipid syndrome","volume":"371","author":"Canaud","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.09.010_bib36","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1093\/rheumatology\/keae397","article-title":"Kidney whole-transcriptome profiling in primary antiphospholipid syndrome reveals complement, interferons and NETs-related gene expression","volume":"63","author":"Tektonidou","year":"2024","journal-title":"Rheumatol (Oxf Engl)"},{"key":"10.1016\/j.ekir.2025.09.010_bib37","doi-asserted-by":"crossref","DOI":"10.1155\/mi\/5568822","article-title":"Inhibiting tyrosine kinase 2 ameliorates antiphospholipid syndrome nephropathy","volume":"2024","author":"Tang","year":"2024","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.ekir.2025.09.010_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102889","article-title":"Renal and vascular outcomes in patients with isolated antiphospholipid syndrome nephropathy","volume":"132","author":"Rousselin","year":"2022","journal-title":"J Autoimmun"},{"key":"10.1016\/j.ekir.2025.09.010_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103180","article-title":"Risk factors for damage accrual in primary antiphospholipid syndrome: a retrospective single-center cohort study","volume":"144","author":"Hoxha","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.ekir.2025.09.010_bib40","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1681\/ASN.V13142","article-title":"Antiphospholipid syndrome nephropathy in systemic lupus erythematosus","volume":"13","author":"Daugas","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.09.010_bib41","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13075-015-0614-5","article-title":"Histological antiphospholipid-associated nephropathy versus lupus nephritis in patients with systemic lupus erythematosus: an observational cross-sectional study with longitudinal follow-up","volume":"17","author":"Gerhardsson","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ekir.2025.09.010_bib42","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.09.010_bib43","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.reuma.2008.12.011","article-title":"Clinical significance of antiphospholipid syndrome nephropathy (APSN) in patients with systemic lupus erythematosus (SLE)","volume":"5","author":"Miranda","year":"2009","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.ekir.2025.09.010_bib44","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/j.ajkd.2003.09.011","article-title":"Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis","volume":"43","author":"Moroni","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.09.010_bib45","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.2169\/internalmedicine.48.2363","article-title":"Antiphospholipid antibodies and renal outcomes in patients with lupus nephritis","volume":"48","author":"Tsuruta","year":"2009","journal-title":"Intern Med"},{"key":"10.1016\/j.ekir.2025.09.010_bib46","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-eular.836","article-title":"THU0308 secondary antiphospholipid syndrome nephropathy and lupus nephritis: a case-control study","volume":"72","author":"P\u00e9rez Vel\u00e1squez","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2025.09.010_bib47","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/0961203310397410","article-title":"Nephropathy associated with antiphospholipid antibodies in patients with systemic lupus erythematosus","volume":"20","author":"Silvari\u00f1o","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2025.09.010_bib48","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1177\/0961203318809177","article-title":"Zonal cortical scarring and tubular thyroidization in kidney biopsies of patients with SLE-histologic indicator for antiphospholipid antibodies","volume":"27","author":"Shah","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2025.09.010_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000924","article-title":"Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"5","author":"Tektonidou","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.ekir.2025.09.010_bib50","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2018-214559","article-title":"Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study","volume":"78","author":"Sciascia","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2025.09.010_bib51","doi-asserted-by":"crossref","DOI":"10.1177\/10760296251364269","article-title":"Evaluating the efficacy and safety of direct oral anticoagulants compared to vitamin K antagonists in patients with antiphospholipid syndrome: updated systematic review and meta-analysis","volume":"31","author":"Alfehaid","year":"2025","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.ekir.2025.09.010_bib52","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s13730-021-00581-2","article-title":"Antiphospholipid antibody syndrome-associated renal thrombotic microangiopathy improved not with Rivaroxaban but with warfarin in a systemic lupus erythematosus patient without lupus nephritis","volume":"10","author":"Horita","year":"2021","journal-title":"CEN Case Rep"},{"key":"10.1016\/j.ekir.2025.09.010_bib53","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/0961203310395051","article-title":"Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions","volume":"20","author":"Cervera","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2025.09.010_bib54","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3899\/jrheum.170561","article-title":"Early renin-angiotensin system blockade improved short-term and longterm renal outcomes in systemic lupus erythematosus patients with antiphospholipid-associated nephropathy","volume":"45","author":"Yue","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ekir.2025.09.010_bib55","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.clim.2015.03.024","article-title":"Oxidative stress and Treg depletion in lupus patients with anti-phospholipid syndrome","volume":"158","author":"wei","year":"2015","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ekir.2025.09.010_bib56","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221079253","article-title":"Successful treatment of sirolimus in a Chinese patient with refractory LN and APS: a case report","volume":"14","author":"Zhang","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.ekir.2025.09.010_bib57","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/art.37759","article-title":"A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ekir.2025.09.010_bib58","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/nep.14375","article-title":"Successful treatment with rituximab in anti-phospholipid syndrome nephropathy associated with systemic lupus erythematosus: a case report and literature review","volume":"29","author":"Choi","year":"2024","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.ekir.2025.09.010_bib59","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10067-017-3793-4","article-title":"TMA secondary to SLE: rituximab improves overall but not renal survival","volume":"37","author":"Sun","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ekir.2025.09.010_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14712598.2025.2484844","article-title":"Biological therapies in thrombocytopenia and primary antiphospholipid syndrome: where are we now?","volume":"25","author":"Radin","year":"2025","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ekir.2025.09.010_bib61","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1136\/annrheumdis-2018-213496","article-title":"Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on Belimumab","volume":"77","author":"Sciascia","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2025.09.010_bib62","first-page":"597","article-title":"Open-label, prospective, phase II descriptive pilot trial of Belimumab therapy for refractory and\/or non-criteria manifestations of antiphospholipid syndrome: study protocol","volume":"41","author":"Sciascia","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ekir.2025.09.010_bib63","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semarthrit.2018.11.005","article-title":"Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series and review of literature","volume":"49","author":"Kello","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ekir.2025.09.010_bib64","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00296-017-3686-5","article-title":"Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence","volume":"37","author":"Sciascia","year":"2017","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ekir.2025.09.010_bib65","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.thromres.2020.10.010","article-title":"Thrombotic antiphospholipid syndrome: a practical guide to diagnosis and management","volume":"198","author":"Sayar","year":"2021","journal-title":"Thromb Res"},{"key":"10.1016\/j.ekir.2025.09.010_bib66","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/art.41891","article-title":"Expert perspective: management of microvascular and catastrophic antiphospholipid syndrome","volume":"73","author":"Erkan","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ekir.2025.09.010_bib67","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/annrheumdis-2013-203622","article-title":"A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients","volume":"73","author":"Erkan","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2025.09.010_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102491","article-title":"The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: a pilot open label randomized prospective study","volume":"19","author":"Kravvariti","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ekir.2025.09.010_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1145145","article-title":"An update on the biologics for the treatment of antiphospholipid syndrome","volume":"14","author":"Yun","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2025.09.010_bib70","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/art.42017","article-title":"Defibrotide inhibits antiphospholipid antibody-mediated neutrophil extracellular trap formation and venous thrombosis","volume":"74","author":"Ali","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ekir.2025.09.010_bib71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/antib13010001","article-title":"Antiphospholipid antibodies associated with native arteriovenous fistula complications in hemodialysis patients: a comprehensive review of the literature","volume":"13","author":"Taghavi","year":"2024","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.ekir.2025.09.010_bib72","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1093\/ndt\/gfq791","article-title":"Thrombophilic factors in Stage V chronic kidney disease patients are largely corrected by renal transplantation","volume":"26","author":"Ghisdal","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.09.010_bib73","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1097\/00007890-200004150-00023","article-title":"Frequency, potential risk and therapeutic intervention in end-stage renal disease patients with antiphospholipid antibody syndrome: a multicenter study","volume":"69","author":"Vaidya","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2025.09.010_bib74","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3389\/fimmu.2018.00468","article-title":"Pretransplant IgA-anti-beta 2 glycoprotein I antibodies as a predictor of early graft thrombosis after renal transplantation in the clinical practice: a multicenter and prospective study","volume":"9","author":"Morales","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2025.09.010_bib75","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1111\/j.1600-6143.2010.03233.x","article-title":"Severe vascular lesions and poor functional outcome in kidney transplant recipients with lupus anticoagulant antibodies","volume":"10","author":"Canaud","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2025.09.010_bib76","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/ndt\/gfx353","article-title":"Anticardiolipin antibodies and 12-month graft function in kidney transplant recipients: a prognosis cohort survey","volume":"33","author":"Gauthier","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.09.010_bib77","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1191\/0961203303lu401oa","article-title":"Antiphospholipid antibodies and renal transplantation: a risk assessment","volume":"12","author":"McIntyre","year":"2003","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2025.09.010_bib78","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1046\/j.1600-6143.2004.00602.x","article-title":"Significance of anticardiolipin antibodies on short and long term allograft survival and function following kidney transplantation","volume":"4","author":"Forman","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2025.09.010_bib79","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1177\/09612033241244508","article-title":"Results and prognosis of kidney transplantation in lupus nephritis: experience of an Argentine center","volume":"33","author":"Ornella","year":"2024","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2025.09.010_bib80","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/j.1399-0012.2012.01625.x","article-title":"Ten-yr renal allograft survival of patients with antiphospholipid antibody syndrome","volume":"26","author":"Vaidya","year":"2012","journal-title":"Clin Transpl"},{"key":"10.1016\/j.ekir.2025.09.010_bib81","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJMc0910965","article-title":"Eculizumab and renal transplantation in a patient with CAPS","volume":"362","author":"Lonze","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.09.010_bib82","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1111\/ajt.12319","article-title":"Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes","volume":"13","author":"Canaud","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2025.09.010_bib83","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/ajt.12540","article-title":"Eculizumab prevents recurrent antiphospholipid antibody syndrome and enables successful renal transplantation","volume":"14","author":"Lonze","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2025.09.010_bib84","series-title":"Eculizumab to enable renal transplantation in patients with history of antiphospholipid antibody syndrome or catastrophic antiphospholipid antibody syndrome. Clinicaltrials.gov. Report No. NCT01029587","year":"2020"},{"key":"10.1016\/j.ekir.2025.09.010_bib85","series-title":"Study of eculizumab for prevention and treatment reperfusion injury in kidney transplantation","year":"2018"},{"key":"10.1016\/j.ekir.2025.09.010_bib86","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1177\/0961203309361353","article-title":"Catastrophic antiphospholipid syndrome (CAPS): update from the \u201cCAPS Registry\u201d","volume":"19","author":"Cervera","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2025.09.010_bib87","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.autrev.2016.09.010","article-title":"Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry","volume":"15","author":"Rodr\u00edguez-Pint\u00f3","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ekir.2025.09.010_bib88","first-page":"1983","article-title":"Antiphospholipid syndrome (APS) nephropathy in catastrophic, primary, and systemic lupus erythematosus-related APS","volume":"35","author":"Tektonidou","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ekir.2025.09.010_bib89","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1007\/s10067-024-07051-x","article-title":"Hematological features and alternate diagnoses in critically ill thrombotic antiphospholipid syndrome patients","volume":"43","author":"Azoulay","year":"2024","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ekir.2025.09.010_bib90","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/1759720X13502919","article-title":"Catastrophic antiphospholipid syndrome: how to diagnose a rare but highly fatal disease","volume":"5","author":"Aguiar","year":"2013","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.ekir.2025.09.010_bib91","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.berh.2016.07.004","article-title":"Catastrophic antiphospholipid syndrome: the current management approach","volume":"30","author":"Rodriguez-Pint\u00f3","year":"2016","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.ekir.2025.09.010_bib92","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/jth.14192","article-title":"McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome","volume":"16","author":"Legault","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ekir.2025.09.010_bib93","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.lpm.2019.10.003","article-title":"Plasma exchange in catastrophic antiphospholipid syndrome","volume":"48","author":"Rodr\u00edguez-Pint\u00f3","year":"2019","journal-title":"Presse Med"},{"key":"10.1016\/j.ekir.2025.09.010_bib94","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev-med-042915-102529","article-title":"Catastrophic antiphospholipid syndrome: candidate therapies for a potentially lethal disease","volume":"68","author":"Unlu","year":"2017","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.ekir.2025.09.010_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103055","article-title":"Eculizumab use in catastrophic antiphospholipid syndrome (CAPS): descriptive analysis from the \u201cCAPS Registry\u201d","volume":"21","author":"L\u00f3pez-Benjume","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ekir.2025.09.010_bib96","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1182\/blood.2020007499","article-title":"Patients with refractory catastrophic antiphospholipid syndrome respond inconsistently to eculizumab","volume":"136","author":"Yelnik","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2025.09.010_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1460317","article-title":"Case report: timing of eculizumab treatment in catastrophic antiphospholipid syndrome","volume":"15","author":"Carrara","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2025.09.010_bib98","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12882-018-0928-z","article-title":"The complex treatment including rituximab in the Management of Catastrophic Antiphospholid Syndrome with renal involvement","volume":"19","author":"Rymarz","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2025.09.010_bib99","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/1759720X14554793","article-title":"Rituximab and its therapeutic potential in catastrophic antiphospolipid syndrome","volume":"7","author":"Rodr\u00edguez-Pint\u00f3","year":"2015","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.ekir.2025.09.010_bib100","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ekir.2025.09.010_bib101","first-page":"215","article-title":"Effective treatment of antiphospholipid syndrome with plasmapheresis and rituximab","volume":"14","author":"Tsagalis","year":"2010","journal-title":"Hippokratia"},{"key":"10.1016\/j.ekir.2025.09.010_bib102","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1177\/0961203318768890","article-title":"Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: the beneficial effect of rituximab treatment","volume":"27","author":"Di\u00f3szegi","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2025.09.010_bib103","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.lpm.2016.07.023","article-title":"2016 review on catastrophic antiphospholipid syndrome","volume":"45","author":"Costedoat-Chalumeau","year":"2016","journal-title":"Presse Med"},{"key":"10.1016\/j.ekir.2025.09.010_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2022.103072","article-title":"Kidney disease in antiphospholipid antibody syndrome: risk factors, pathophysiology and management","volume":"21","author":"Scheen","year":"2022","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ekir.2025.09.010_bib105","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/ard.62.10.999","article-title":"Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension","volume":"62","author":"Sangle","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.ekir.2025.09.010_bib106","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1136\/annrheumdis-2020-eular.2941","article-title":"Sat0239 long term outcomes in patients with antiphospholipid syndrome and renal artery stenosis","volume":"79","author":"Villar","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2025.09.010_bib107","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/annrheumdis-2016-eular.2391","article-title":"THU0283 anticoagulation and long-term outcomes in patients with renal artery stenosis and antiphospholipid syndrome","volume":"75","author":"Casian","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2025.09.010_bib108","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.kint.2016.06.026","article-title":"Antiphospholipid syndrome and kidney disease","volume":"91","author":"Bienaim\u00e9","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.09.010_bib109","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/0140-6736(93)91213-6","article-title":"Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus","volume":"341","author":"Vaarala","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2025.09.010_bib110","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1046\/j.1365-2249.1997.d01-948.x","article-title":"Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages","volume":"107","author":"Hasunuma","year":"1997","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ekir.2025.09.010_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2022.102813","article-title":"Cardiovascular disease risk in antiphospholipid syndrome: thrombo-inflammation and atherothrombosis","volume":"128","author":"Tektonidou","year":"2022","journal-title":"J Autoimmun"},{"key":"10.1016\/j.ekir.2025.09.010_bib112","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/096120330000900112","article-title":"A reversible bilateral renal artery stenosis in association with antiphospholipid syndrome","volume":"9","author":"Remondino","year":"2000","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2025.09.010_bib113","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.semarthrit.2006.01.001","article-title":"Antiphospholipid syndrome and the kidneys","volume":"35","author":"Uthman","year":"2006","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ekir.2025.09.010_bib114","first-page":"479","article-title":"Malignant hypertension in antiphospholipid syndrome without overt lupus nephritis","volume":"11","author":"Cacoub","year":"1993","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ekir.2025.09.010_bib115","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10067-017-3549-1","article-title":"Clinical characteristics and laboratory findings of 252 Chinese patients with anti-phospholipid syndrome: comparison with Euro-Phospholipid cohort","volume":"36","author":"Shi","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ekir.2025.09.010_bib116","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/rheumatology\/keaa542","article-title":"Morbidity and mortality in antiphospholipid syndrome based on cluster analysis: a 10-year longitudinal cohort study","volume":"60","author":"Ogata","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ekir.2025.09.010_bib117","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1177\/0961203320933009","article-title":"Long-term follow-up of antiphospholipid syndrome: real-life experience from a single center","volume":"29","author":"Serrano","year":"2020","journal-title":"Lupus"},{"key":"10.1016\/j.ekir.2025.09.010_bib118","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1538-7836.2009.03674.x","article-title":"Clinical course of high-risk patients diagnosed with antiphospholipid syndrome","volume":"8","author":"Pengo","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ekir.2025.09.010_bib119","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/acr.24468","article-title":"Characteristics of patients with antiphospholipid antibody positivity in the APS ACTION international clinical database and repository","volume":"74","author":"Sevim","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ekir.2025.09.010_bib120","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/j.1464-410X.1994.tb07137.x","article-title":"Renal vein thrombosis caused by primary antiphospholipid syndrome","volume":"74","author":"Morgan","year":"1994","journal-title":"Br J Urol"},{"key":"10.1016\/j.ekir.2025.09.010_bib121","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1093\/ndt\/10.10.1929","article-title":"Renal vein thrombosis as first clinical manifestation of the primary antiphospholipid syndrome","volume":"10","author":"Ko","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.09.010_bib122","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00467-011-1787-z","article-title":"Primary antiphospholipid syndrome presenting as renal vein thrombosis and membranous nephropathy","volume":"26","author":"Chaturvedi","year":"2011","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.ekir.2025.09.010_bib123","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1055\/s-0033-1343887","article-title":"Thrombosis in nephrotic syndrome","volume":"39","author":"Barbano","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.ekir.2025.09.010_bib124","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1136\/annrheumdis-2019-215213","article-title":"EULAR recommendations for the management of antiphospholipid syndrome in adults","volume":"78","author":"Tektonidou","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ekir.2025.09.010_bib125","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40620-024-02166-5","article-title":"Predictors of renal outcomes and mortality in patients with renal vein thrombosis: a retrospective multicenter study","volume":"38","author":"Mohamed","year":"2025","journal-title":"J Nephrol"},{"key":"10.1016\/j.ekir.2025.09.010_bib126","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1159\/000529229","article-title":"Antiphospholipid syndrome and kidney involvement","volume":"48","author":"De Simone","year":"2023","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.ekir.2025.09.010_bib127","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000512228","article-title":"A rare case of unilateral renal cortical necrosis","volume":"11","author":"Haaskjold","year":"2021","journal-title":"Case Rep Nephrol Dial"},{"key":"10.1016\/j.ekir.2025.09.010_bib128","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1053\/j.ajkd.2011.02.381","article-title":"Bilateral acute renal cortical necrosis in SLE-associated antiphospholipid syndrome","volume":"57","author":"Kim","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.09.010_bib129","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4103\/1319-2442.111064","article-title":"Post-partum bilateral renal cortical necrosis in antiphospholipid syndrome and systemic lupus erythematosus","volume":"24","author":"Vellanki","year":"2013","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.ekir.2025.09.010_bib130","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4137\/CCRep.S11633","article-title":"Bilateral renal infarction in a lupus patient: an unusual pathology","volume":"6","author":"Padilla-Fern\u00e1ndez","year":"2013","journal-title":"Clin Med Insights Case Rep"},{"key":"10.1016\/j.ekir.2025.09.010_bib131","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hdi.12847","article-title":"Antiphospholipid antibodies in end-stage renal disease: a systematic review and meta-analysis","volume":"24","author":"Ames","year":"2020","journal-title":"Hemodial Int"},{"key":"10.1016\/j.ekir.2025.09.010_bib132","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222102","article-title":"Thrombophilic risk factors in hemodialysis: association with early vascular access occlusion and patient survival in long-term follow-up","volume":"14","author":"Grupp","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2025.09.010_bib133","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/0886022X.2021.2011746","article-title":"Thrombophilic risk factors and ABO blood group profile for arteriovenous access failure in end stage kidney disease patients: a single-center experience","volume":"44","author":"Anapalli","year":"2022","journal-title":"Ren Fail"},{"key":"10.1016\/j.ekir.2025.09.010_bib134","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2024ck1841da","article-title":"Comparative analysis of anti-phospholipid-antibody positivity and confirmation as potential risk factors for arteriovenous fistula thrombosis in patients on hemodialysis: FR-PO532","volume":"35","author":"Taghavi","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.09.010_bib135","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/ki.2011.477","article-title":"IgA antibodies against \u03b22 glycoprotein I in hemodialysis patients are an independent risk factor for mortality","volume":"81","author":"Serrano","year":"2012","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.09.010_bib136","doi-asserted-by":"crossref","first-page":"e202","DOI":"10.1016\/j.thromres.2013.03.003","article-title":"Hemodialysis duration, human platelet antigen HPA-3 and IgA isotype of anti-\u03b22glycoprotein I antibodies are associated with native arteriovenous fistula failure in Tunisian hemodialysis patients","volume":"131","author":"Hadhri","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.ekir.2025.09.010_bib137","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1159\/000065580","article-title":"Vascular access thrombosis is not related to presence of antiphospholipid antibodies in patients on chronic hemodialysis","volume":"92","author":"Palomo","year":"2002","journal-title":"Nephron"},{"key":"10.1016\/j.ekir.2025.09.010_bib138","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0272-6386(03)00860-6","article-title":"Hypercoagulability, a serious problem in patients with ESRD on maintenance hemodialysis, and its correction after kidney transplantation","volume":"42","author":"Nampoory","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.09.010_bib139","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0272-6386(12)80383-0","article-title":"Frequent hemodialysis graft thrombosis: association with antiphospholipid antibodies","volume":"23","author":"Prieto","year":"1994","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.09.010_bib140","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/0272-6386(95)90656-8","article-title":"Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis","volume":"26","author":"Prakash","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.09.010_bib141","doi-asserted-by":"crossref","first-page":"361","DOI":"10.5455\/medarh.2014.68.361-363","article-title":"Exhausting multiple hemodialysis access failures","volume":"68","author":"Bolleke","year":"2014","journal-title":"Med Arch"},{"key":"10.1016\/j.ekir.2025.09.010_bib142","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2025.2486566","article-title":"Antiphospholipid antibody positivity and its potential impact on stent patency and long-term outcomes in central venous occlusive disease among hemodialysis patients: a call for targeted therapeutic strategies","volume":"47","author":"Taghavi","year":"2025","journal-title":"Ren Fail"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925005650?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925005650?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T20:53:44Z","timestamp":1783025624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024925005650"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":142,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2468024925005650"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2025.09.010","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antiphospholipid Syndrome and the Kidney","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}